Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ALKBH5_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ALKBH5_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ALKBH5_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ALKBH5_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ALKBH5_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ALKBH5_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ALKBH5_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00711664 | Oral cavity | OSCC | ribonucleoprotein complex localization | 59/7305 | 77/18723 | 1.91e-11 | 6.57e-10 | 59 |
GO:000166619 | Oral cavity | OSCC | response to hypoxia | 177/7305 | 307/18723 | 2.21e-11 | 7.50e-10 | 177 |
GO:00714264 | Oral cavity | OSCC | ribonucleoprotein complex export from nucleus | 58/7305 | 76/18723 | 3.78e-11 | 1.23e-09 | 58 |
GO:003629319 | Oral cavity | OSCC | response to decreased oxygen levels | 182/7305 | 322/18723 | 1.14e-10 | 3.41e-09 | 182 |
GO:006101316 | Oral cavity | OSCC | regulation of mRNA catabolic process | 105/7305 | 166/18723 | 2.04e-10 | 5.82e-09 | 105 |
GO:00064055 | Oral cavity | OSCC | RNA export from nucleus | 61/7305 | 84/18723 | 4.03e-10 | 1.08e-08 | 61 |
GO:004348716 | Oral cavity | OSCC | regulation of RNA stability | 106/7305 | 170/18723 | 5.65e-10 | 1.47e-08 | 106 |
GO:004348816 | Oral cavity | OSCC | regulation of mRNA stability | 99/7305 | 158/18723 | 1.41e-09 | 3.39e-08 | 99 |
GO:00064063 | Oral cavity | OSCC | mRNA export from nucleus | 45/7305 | 59/18723 | 6.19e-09 | 1.31e-07 | 45 |
GO:00714273 | Oral cavity | OSCC | mRNA-containing ribonucleoprotein complex export from nucleus | 45/7305 | 59/18723 | 6.19e-09 | 1.31e-07 | 45 |
GO:00315034 | Oral cavity | OSCC | protein-containing complex localization | 123/7305 | 220/18723 | 2.54e-07 | 4.00e-06 | 123 |
GO:00094511 | Oral cavity | OSCC | RNA modification | 95/7305 | 167/18723 | 2.05e-06 | 2.62e-05 | 95 |
GO:000640319 | Oral cavity | LP | RNA localization | 105/4623 | 201/18723 | 3.34e-17 | 5.36e-15 | 105 |
GO:190331119 | Oral cavity | LP | regulation of mRNA metabolic process | 129/4623 | 288/18723 | 5.70e-14 | 6.10e-12 | 129 |
GO:000691318 | Oral cavity | LP | nucleocytoplasmic transport | 130/4623 | 301/18723 | 1.19e-12 | 9.77e-11 | 130 |
GO:005116918 | Oral cavity | LP | nuclear transport | 130/4623 | 301/18723 | 1.19e-12 | 9.77e-11 | 130 |
GO:003465518 | Oral cavity | LP | nucleobase-containing compound catabolic process | 161/4623 | 407/18723 | 1.61e-11 | 1.15e-09 | 161 |
GO:000640119 | Oral cavity | LP | RNA catabolic process | 118/4623 | 278/18723 | 4.98e-11 | 3.12e-09 | 118 |
GO:005065715 | Oral cavity | LP | nucleic acid transport | 78/4623 | 163/18723 | 1.11e-10 | 6.44e-09 | 78 |
GO:005065815 | Oral cavity | LP | RNA transport | 78/4623 | 163/18723 | 1.11e-10 | 6.44e-09 | 78 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ALKBH5 | SNV | Missense_Mutation | novel | c.579N>G | p.Asn193Lys | p.N193K | Q6P6C2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD |
ALKBH5 | SNV | Missense_Mutation | | c.877N>C | p.Glu293Gln | p.E293Q | Q6P6C2 | protein_coding | deleterious(0.04) | possibly_damaging(0.484) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ALKBH5 | SNV | Missense_Mutation | | c.871N>T | p.Arg291Trp | p.R291W | Q6P6C2 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AO-A0J3-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD |
ALKBH5 | SNV | Missense_Mutation | novel | c.458N>G | p.Glu153Gly | p.E153G | Q6P6C2 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-D8-A140-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin+cyclophosphamid | SD |
ALKBH5 | insertion | Nonsense_Mutation | novel | c.1030_1031insTTGATTCTCAAGAGATGGCTTATGGGTCTTCGGGGCCTTG | p.Lys344IlefsTer14 | p.K344Ifs*14 | Q6P6C2 | protein_coding | | | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
ALKBH5 | SNV | Missense_Mutation | | c.979N>T | p.Arg327Cys | p.R327C | Q6P6C2 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.88) | TCGA-C5-A1MJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ALKBH5 | SNV | Missense_Mutation | | c.1168N>G | p.Lys390Glu | p.K390E | Q6P6C2 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.981) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
ALKBH5 | SNV | Missense_Mutation | rs751699434 | c.1117N>A | p.Glu373Lys | p.E373K | Q6P6C2 | protein_coding | tolerated_low_confidence(0.09) | benign(0.212) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ALKBH5 | SNV | Missense_Mutation | | c.686G>A | p.Gly229Asp | p.G229D | Q6P6C2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ALKBH5 | SNV | Missense_Mutation | | c.245N>T | p.Ala82Val | p.A82V | Q6P6C2 | protein_coding | tolerated(0.44) | possibly_damaging(0.837) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD |